Neuroleptic malignant syndrome (NMS) is an uncommon but serious and potentially fatal adverse drug effect caused by dopamine receptor blockade. The syndrome is most closely associated with use of typical, and less frequently atypical, antipsychotics, with an incidence rate of up to 1.4% in patients being treated with these drugs. However, other drugs acting as D2 receptor antagonists, such as antihistamines and antiemetics, can also cause the syndrome. Antidepressants, carbamazepine, and lithium (Konstantakopoulos et al., 2009; Patil et al., 2016) have sometimes been implicated as possible exacerbating factors.
{"title":"Drug-associated neuroleptic malignant syndrome","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31275","DOIUrl":"https://doi.org/10.1002/pu.31275","url":null,"abstract":"<p>Neuroleptic malignant syndrome (NMS) is an uncommon but serious and potentially fatal adverse drug effect caused by dopamine receptor blockade. The syndrome is most closely associated with use of typical, and less frequently atypical, antipsychotics, with an incidence rate of up to 1.4% in patients being treated with these drugs. However, other drugs acting as D2 receptor antagonists, such as antihistamines and antiemetics, can also cause the syndrome. Antidepressants, carbamazepine, and lithium (Konstantakopoulos et al., 2009; Patil et al., 2016) have sometimes been implicated as possible exacerbating factors.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment discontinuation less likely with methadone than buprenorphine/naloxone","authors":"","doi":"10.1002/pu.31267","DOIUrl":"https://doi.org/10.1002/pu.31267","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143110248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Elinzanetant effective for menopausal vasomotor symptoms","authors":"","doi":"10.1002/pu.31265","DOIUrl":"https://doi.org/10.1002/pu.31265","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atypical antipsychotics are frequently used in conjunction with selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine/serotonin reuptake inhibitors (SNRIs), but data on potential pharmacokinetic interactions between specific combinations are limited.
{"title":"Quetiapine co-administration with fluvoxamine and duloxetine","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31262","DOIUrl":"https://doi.org/10.1002/pu.31262","url":null,"abstract":"<p>Atypical antipsychotics are frequently used in conjunction with selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine/serotonin reuptake inhibitors (SNRIs), but data on potential pharmacokinetic interactions between specific combinations are limited.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Long-acting injectable (LAI) formulations of paliperidone and aripiprazole were among the most effective antipsychotics for limiting patient relapse in a comparative effectiveness study using health care register data for patients with schizophrenia. The 3-month formulation of LAI paliperidone was associated with the lowest risk of the adverse outcomes.
{"title":"LAI antipsychotics show effective results in comparative analysis","authors":"","doi":"10.1002/pu.31263","DOIUrl":"https://doi.org/10.1002/pu.31263","url":null,"abstract":"<p>Long-acting injectable (LAI) formulations of paliperidone and aripiprazole were among the most effective antipsychotics for limiting patient relapse in a comparative effectiveness study using health care register data for patients with schizophrenia. The 3-month formulation of LAI paliperidone was associated with the lowest risk of the adverse outcomes.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"3-4"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drugs in medication classes commonly used to treat type 2 diabetes and obesity appear to improve substance use outcomes in patients with opioid use disorder (OUD) and alcohol use disorder (AUD), a retrospective cohort study has found. Patients receiving these medications experienced significantly lower rates of opioid overdose and alcohol intoxication. Study results were published online Oct. 16, 2024, in Addiction.
{"title":"Weight-loss drugs appear beneficial for patients with substance use disorders","authors":"","doi":"10.1002/pu.31260","DOIUrl":"https://doi.org/10.1002/pu.31260","url":null,"abstract":"<p>Drugs in medication classes commonly used to treat type 2 diabetes and obesity appear to improve substance use outcomes in patients with opioid use disorder (OUD) and alcohol use disorder (AUD), a retrospective cohort study has found. Patients receiving these medications experienced significantly lower rates of opioid overdose and alcohol intoxication. Study results were published online Oct. 16, 2024, in <i>Addiction</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A systematic review and network meta-analysis encompassing 68 randomized trials has concluded that the antipsychotics haloperidol, fluphenazine, and clozapine ranked lowest on measures of cognition in patients with schizophrenia and related disorders. There were few clear differences overall among the antipsychotics studied, the investigators reported. Results were published online Oct. 16, 2024, in JAMA Psychiatry.
{"title":"Review: Haloperidol, fluphenazine, clozapine show poor results on cognition","authors":"","doi":"10.1002/pu.31261","DOIUrl":"https://doi.org/10.1002/pu.31261","url":null,"abstract":"<p>A systematic review and network meta-analysis encompassing 68 randomized trials has concluded that the antipsychotics haloperidol, fluphenazine, and clozapine ranked lowest on measures of cognition in patients with schizophrenia and related disorders. There were few clear differences overall among the antipsychotics studied, the investigators reported. Results were published online Oct. 16, 2024, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Gepirone ER not linked to sexual dysfunction in patients with depression","authors":"","doi":"10.1002/pu.31268","DOIUrl":"https://doi.org/10.1002/pu.31268","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinic patients remained stable after guided tapering of antipsychotics","authors":"","doi":"10.1002/pu.31269","DOIUrl":"https://doi.org/10.1002/pu.31269","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号